Securin predicts aneuploidy and survival in breast cancer

Histopathology

Volumn 60, Issue 4, 2012, Pages 586-596

  Karra, Henna ^a   Pitkänen, Reino ^b   Nykänen, Marjukka ^b   Talvinen, Kati ^a   Kuopio, Teijo ^b   Söderström, Mirva ^a   Kronqvist, Pauliina ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

Aneuploidy; Breast cancer; DNA content; Prognosis; Securin

Indexed keywords

SECURIN;

ADULT; AGED; ANEUPLOIDY; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL FRACTIONATION; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DNA CONTENT; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE CYTOMETRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL PREDICTION; SURVIVAL TIME; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE;

EID: 84857369493     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04107.x     Document Type: Article

References (52)

1. Hamid T, Kakar SS. PTTG/securin activates expression of p53 and modulates its function. Mol. Cancer 2004; 3; 18.
2. Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocr. Relat. Cancer 2008; 15; 721-743.
3. Smith VE, Franklyn JA, McCabe CJ. Pituitary tumor-transforming gene and its binding factor in endocrine cancer. Expert Rev. Mol. Med. 2010; 12; e38.
4. Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr. Rev. 2007; 28; 165-186.
5. Hornig NC, Knowles PP, McDonald NQ, Uhlmann F. The dual mechanism of separase regulation by securin. Curr. Biol. 2002; 12; 973-982.
6. Nasmyth K, Peters JM, Uhlmann F. Splitting the chromosome: cutting the ties that bind sister chromatids. Science 2000; 288; 1379-1385.
7. Waizenegger I, Gimenez-Abian JF, Wernic D, Peters JM. Regulation of human separase by securin binding and autocleavage. Curr. Biol. 2002; 12; 1368-1378.
8. Yu R, Ren SG, Horwitz GA, Wang Z, Melmed S. Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol. Endocrinol. 2000; 14; 1137-1146.
9. Zou H, McGarry TJ, Bernal T, Kirschner MW. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999; 285; 418-422.
10. Zur A, Brandeis M. Securin degradation is mediated by fzy and fzr, and is required for complete chromatid separation but not for cytokinesis. EMBO J. 2001; 20; 792-801.
11. Wirth KG, Wutz G, Kudo NR et al. Separase: a universal trigger for sister chromatid disjunction but not chromosome cycle progression. J. Cell Biol. 2006; 172; 847-860.
12. Bernal JA, Roche M, Mendez-Vidal C, Espina A, Tortolero M, Pintor-Toro JA. Proliferative potential after DNA damage and non-homologous end joining are affected by loss of securin. Cell Death Differ. 2008; 15; 202-212.
13. Romero F, Multon MC, Ramos-Morales F et al. Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res. 2001; 29; 1300-1307.
14. Bannon JH, McGee MM. Understanding the role of aneuploidy in tumorigenesis. Biochem. Soc. Trans. 2009; 37(Pt 4); 910-913.
15. Weaver BA, Cleveland DW. The role of aneuploidy in promoting and suppressing tumors. J. Cell Biol. 2009; 185; 935-937.
16. Duigou F, Herlin P, Marnay J, Michels JJ. Variation of flow cytometric DNA measurement in 1, 485 primary breast carcinomas according to guidelines for DNA histogram interpretation. Cytometry 2000; 42; 35-42.
17. Li L, Mu K, Zhou G, Lan L, Auer G, Zetterberg A. Genomic instability and proliferative activity as risk factors for distant metastases in breast cancer. Br. J. Cancer 2008; 99; 513-519.
18. Mandard AM, Denoux Y, Herlin P et al. Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density. Cancer 2000; 89; 1748-1757.
19. Millot C, Dufer J. Clinical applications of image cytometry to human tumour analysis. Histol. Histopathol. 2000; 15; 1185-1200.
20. Yildirim-Assaf S, Coumbos A, Hopfenmuller W, Foss HD, Stein H, Kuhn W. The prognostic significance of determining DNA content in breast cancer by DNA image cytometry: the role of high grade aneuploidy in node negative breast cancer. J. Clin. Pathol. 2007; 60; 649-655.
21. Tong Y, Tan Y, Zhou C, Melmed S. Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene 2007; 26; 5596-5605.
22. Yu R, Heaney AP, Lu W, Chen J, Melmed S. Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J. Biol. Chem. 2000; 275; 36502-36505.
23. Christopoulou L, Moore JD, Tyler-Smith C. Over-expression of wild-type Securin leads to aneuploidy in human cells. Cancer Lett. 2003; 202; 213-218.
24. Yu R, Lu W, Chen J, McCabe CJ, Melmed S. Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology 2003; 144; 4991-4998.
25. Kim D, Pemberton H, Stratford AL et al. Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene 2005; 24; 4861-4866.
26. Kim DS, Franklyn JA, Smith VE et al. Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity. Carcinogenesis 2007; 28; 749-759.
27. Shibata Y, Haruki N, Kuwabara Y et al. Expression of PTTG (pituitary tumor transforming gene) in esophageal cancer. Jpn. J. Clin. Oncol. 2002; 32; 233-237.
28. Saez C, Martinez-Brocca MA, Castilla C et al. Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 2006; 91; 1404-1409.
29. Fujii T, Nomoto S, Koshikawa K et al. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology 2006; 43; 1267-1275.
30. Talvinen K, Tuikkala J, Gronroos J et al. Biochemical and clinical approaches in evaluating the prognosis of colon cancer. Anticancer Res. 2006; 26; 4745-4751.
31. Winnepenninckx V, biec-Rychter M, Belien JA et al. Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma. Mod. Pathol. 2006; 19; 1170-1180.
32. Genkai N, Homma J, Sano M, Tanaka R, Yamanaka R. Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. Oncol. Rep. 2006; 15; 1569-1574.
33. Kakar SS, Jennes L. Molecular cloning and characterization of the tumor transforming gene (TUTR1): a novel gene in human tumorigenesis. Cytogenet. Cell Genet. 1999; 84; 211-216.
34. Thompson AD III, Kakar SS. Insulin and IGF-1 regulate the expression of the pituitary tumor transforming gene (PTTG) in breast tumor cells. FEBS Lett. 2005; 579; 3195-3200.
35. Ogbagabriel S, Fernando M, Waldman FM, Bose S, Heaney AP. Securin is overexpressed in breast cancer. Mod. Pathol. 2005; 18; 985-990.
36. Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M. PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast 2004; 13; 80-81.
37. Chen CC, Chang TW, Chen FM et al. Combination of multiple mRNA markers (PTTG1, Survivin, UbcH10 and TK1) in the diagnosis of Taiwanese patients with breast cancer by membrane array. Oncology 2006; 70; 438-446.
38. Talvinen K, Karra H, Hurme S et al. Securin promotes the identification of favourable outcome in invasive breast cancer. Br. J. Cancer 2009; 101; 1005-1010.
39. Solbach C, Roller M, Peters S, Nicoletti M, Kaufmann M, Knecht R. Pituitary tumor-transforming gene (PTTG): a novel target for anti-tumor therapy. Anticancer Res. 2005; 25; 121-125.
40. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 1998; 4; 844-847.
41. Talvinen K, Tuikkala J, Nevalainen O et al. Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer. Br. J. Cancer 2008; 99; 335-340.
42. Hamid T, Malik MT, Kakar SS. Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells. Mol. Cancer 2005; 4; 3.
43. Pei L. Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. J. Biol. Chem. 2001; 276; 8484-8491.
44. Cho-Rok J, Yoo J, Jang YJ et al. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology 2006; 43; 1042-1052.
45. Mu YM, Oba K, Yanase T et al. Human pituitary tumor transforming gene (hPTTG) inhibits human lung cancer A549 cell growth through activation of p21(WAF1/CIP1). Endocr. J. 2003; 50; 771-781.
46. Saez C, Japon MA, Ramos-Morales F et al. hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene 1999; 18; 5473-5476.
47. Zhang X, Horwitz GA, Heaney AP et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J. Clin. Endocrinol. Metab. 1999; 84; 761-767.
48. Zhang X, Horwitz GA, Prezant TR et al. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol. Endocrinol. 1999; 13; 156-166.
49. Cortes-Mateos MJ, Martin D, Sandoval S et al. Automated microscopy to evaluate surgical specimens via touch prep in breast cancer. Ann. Surg. Oncol. 2009; 16; 709-720.
50. Jallepalli PV, Waizenegger IC, Bunz F et al. Securin is required for chromosomal stability in human cells. Cell 2001; 105; 445-457.
51. Wang Z, Melmed S. Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. J. Biol. Chem. 2000; 275; 7459-7461.
52. Thompson SL, Compton DA. Examining the link between chromosomal instability and aneuploidy in human cells. J. Cell Biol. 2008; 180; 665-672.